An anti-CD6 antibody for the treatment of COVID-19 patients with cytokine-release syndrome: report of three cases.
Immunotherapy
; 13(4): 289-295, 2021 03.
Article
in English
| MEDLINE | ID: covidwho-1007063
ABSTRACT
In COVID-19, the inflammatory cytokine-release syndrome is associated with the progression of the disease. Itolizumab is a monoclonal antibody that recognizes human CD6 expressed in activated T cells. The antibody has shown to be safe and efficacious in the treatment of moderate to severe psoriasis. Its effect is associated with the reduction of pro-inflammatory cytokines release, including IFN-γ, IL-6 and TNF-α. Here, we report the outcome of three severe and critically ill COVID-19 patients treated with itolizumab as part of an expanded access protocol. Itolizumab was able to reduce IL-6 concentrations in all the patients. Two of the three patients showed respiratory and radiological improvement and were fully recovered. We hypothesize this anti-inflammatory therapy in addition to antiviral and anticoagulant therapy could reduce COVID-19 associated morbidity and mortality.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Antigens, Differentiation, T-Lymphocyte
/
Antigens, CD
/
Antibodies, Monoclonal, Humanized
/
Cytokine Release Syndrome
/
COVID-19 Drug Treatment
/
Anti-Inflammatory Agents
Type of study:
Case report
/
Prognostic study
Limits:
Female
/
Humans
/
Male
/
Middle aged
Language:
English
Journal:
Immunotherapy
Journal subject:
Allergy and Immunology
/
Therapeutics
Year:
2021
Document Type:
Article
Affiliation country:
Imt-2020-0235
Similar
MEDLINE
...
LILACS
LIS